PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Ventana Medical Systems, Inc. · Decision date Dec 15, 2025
What did the FDA approve?
FDA records P990081/S059 as a supplement to PMA P990081, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Dec 15, 2025.
FDA approval order statement
This 180-day supplement is to expand labeling of the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Dec 15, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P990081/S059
- Regulatory pathway
- PMA supplement
- Applicant
- Ventana Medical Systems, Inc.
- Product code
- MVC
- Decision code
- APPR
- Decision date
- Dec 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.
- Applicant
- Ventana Medical Systems, Inc.
- Product code
- MVC
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P990081/S059 received
Application receipt date recorded by FDA.
P990081/S059 · FDA decision
Normal 180 Day Track
P990081/S058 · Related supplement
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
P990081/S060 · Related supplement
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Timeline entries are records held by MedtechLedger for P990081. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990081
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ventana Medical Systems, Inc. | PMA supplement | May 15, 2026 | FDA | |
| Ventana Medical Systems, Inc. | PMA supplement | Aug 25, 2026 | FDA |
Explore the linked device profile
Other records with product code MVC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HercepTestP980018/S027 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
BOND Oracle HER2 IHC SystemP090015/S014 | Leica Biosystems | PMA supplement | Jun 4, 2026 | FDA |
HercepTestP980018/S026 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Jan 28, 2026 | FDA |
DAKO HERCEPTESTP980018 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA approval | Sep 25, 1998 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P990081/S059
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


